Erasca doses first patient in Phase 1b SEACRAFT-1 trial of naporafenib plus trametinib for RAS Q61X tumors

Erasca, Inc.

SEACRAFT-1 evaluates pan-RAF inhibitor naporafenib + MEK inhibitor trametinib in RAS Q61X solid tumors; addressable patient population >150k in US/Europe.
Signal-seeking efficacy data expected between Q2 and Q4 2024.
Pivotal Phase 3 SEACRAFT-2 trial for NRAS-mutant melanoma on track to start H1 2024.
Naporafenib licensed from Novartis; Erasca has not conducted prior clinical trials of the drug.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.